𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mean platelet volume as a fibrosis marker in patients with chronic hepatitis B

✍ Scribed by Fuat Ekiz; Osman Yüksel; Erdem Koçak; Barış Yılmaz; Akif Altınbaş; Şahin Çoban; İlhami Yüksel; Oğuz Üsküdar; Seyfettin Köklü


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
86 KB
Volume
25
Category
Article
ISSN
0887-8013

No coin nor oath required. For personal study only.

✦ Synopsis


Introduction:

Many noninvasive tests have been studied for the diagnosis and determining the liver fibrosis score (lfs). in this study, we aimed to research the correlation of mean platelet volume (mpv) and stage of liver fibrosis in patients with chronic hepatitis b (chb).

Patients and methods:

Fifty-nine patients with chb were enrolled retrospectively into the study. age-sex matched 25 healthy subjects were used as control group. the following data were obtained from computerized patient registry database: hbv-dna level, hepatitis b e-antigen seropositivity, liver enzymes and function tests, white blood cell count, platelet count, hemoglobin, histological activity index, lfs, and mpv. patients were divided into two groups: patients without significant fibrosis (f0, f1, or f2) (group 1) and patients with advanced fibrosis (f3, f4) (group 2).

Results:

A statistically significant increase in mpv was seen in patients with chb compared with healthy controls (8.49±0.84 fl vs.7.65±0.42 fl, p<0.001). receiver operating characteristic curve analysis suggested that the optimum mpv level cut-off points for chb was 8.0 fl, with sensitivity, specificity, ppv, and npv of 68, 76, 86, and 50%, respectively. mpv levels were significantly higher in group 2 (8.91±0.94 fl, p: 0.009) compared with group 1 (8.32±0.74 fl). roc curve analysis suggested that the optimum mpv level cut-off points for group 2 was 8.45 fl, with sensitivity, specificity, positive and negative predictive value of 77, 59, 45, and 85%, respectively. multivariable logistic regression model, which consisted of hai, alt, hbv-dna, platelet count, and mpv, was performed. we showed that mpv was independently associated with advanced fibrosis (p: 0.031).

Conclusion:

We suggest that mpv might help in the assessment of fibrosis in chb. it should not be considered a stand-alone test for this use owing to nonspecificity with other diseases.


📜 SIMILAR VOLUMES


Mean platelet volume as a marker of incr
✍ Naim Alkhouri; Gaurav Kistangari; Carla Campbell; Rocio Lopez; Nizar N. Zein; Ar 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB

Nonalcoholic fatty liver disease (NAFLD) is a burgeoning medical problem that affects 20%-34% of the population in Western countries. 1 Although the prevalence of NAFLD is somewhat lower in Asia, the frequency is increasing, and the disorder is now being seen in younger individuals. 2,3 NAFLD is a m

Relationship of serum fibrosis markers w
✍ Robert J. Fontana; Zachary D. Goodman; Jules L. Dienstag; Herbert L. Bonkovsky; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB 👁 1 views

This study determined the utility of a panel of serum fibrosis markers along with routine laboratory tests in estimating the likelihood of histological cirrhosis in a cohort of prior nonresponders with chronic hepatitis C. The relationship between serum markers and quantitative hepatic collagen cont

Simple blood tests as noninvasive marker
✍ Leonardo L. Schiavon; Janaína L. N. Schiavon; Roberto J. Carvalho Filho; Juliana 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB 👁 2 views

HCV infection is common among patients with end-stage renal disease (ESRD) on hemodialysis, and it has been considered an independent risk factor for mortality in this setting. Although liver biopsy in ESRD patients with HCV infection is useful before kidney transplantation, it carries a high risk o

Prediction of significant fibrosis in HB
✍ Min-De Zeng; Lun-Gen Lu; Yi-Min Mao; De-Kai Qiu; Ji-Qiang Li; Mo-Bin Wan; Cheng- 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 2 views

A model was constructed consisting of clinical and serum variables to discriminate between hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients with and without significant fibrosis (stages 2-4 vs. stages 0-1). Consecutive treatment-naive CHB patients who underwent liver biopsy

Peginterferon alpha-2b is safe and effec
✍ Erik H. C. J. Buster; Bettina E. Hansen; Maria Buti; Jean Delwaide; Claus Nieder 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 2 views

for the HBV 99-01 study group Chronic hepatitis B (CHB) patients with advanced fibrosis are often not considered for treatment with peginterferon (PEG-IFN) because IFN therapy may precipitate immunological flares, potentially inducing hepatic decompensation. We investigated the efficacy and safety o